Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinomaResearch in context

Summary: Background: Simlukafusp alfa (FAP-IL2v) is an immune cytokine engineered to selectively promote immune responses in the tumour microenvironment. We evaluated the antitumour activity and safety of FAP-IL2v plus atezolizumab in recurrent and/or metastatic cervical squamous cell carcinoma (SC...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Loic Verlingue, Antoine Italiano, Hans Prenen, Eva Maria Guerra Alia, Diego Tosi, Ruth Perets, Iwona Lugowska, Vladimir Moiseyenko, Mahmut Gumus, Cagatay Arslan, Colin R. Lindsay, Sanjeev Deva, Álvaro Taus, Ana Oaknin, Sylvie Rottey, Irfan Cicin, Sema Sezgin Goksu, Alexey Smolin, Susana Roselló-Keränen, Christin Habigt, Daniel Marbach, Christophe Boetsch, David Dejardin, Nassim Sleiman, Stefan Evers, Muriel Richard, Caroline Ardeshir, Jehad Charo, Anton Kraxner, Volker Teichgräber, Nino Keshelava, Rafal Dziadziuszko
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Elsevier 2024-11-01
Sarja:	EBioMedicine
Aiheet:	Cervical cancer Squamous cell carcinoma Immunotherapy IL-2 PD-L1
Linkit:	http://www.sciencedirect.com/science/article/pii/S2352396424004109
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!